HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Exanthem caused by Chlamydia psittaci — Clinical Guidelines

Overview

Exanthem caused by Chlamydia psittaci primarily affects birds, particularly psittacine species such as parrots, leading to clinical syndromes collectively known as psittacosis 11. This zoonotic disease can occasionally transmit to humans, causing respiratory symptoms, fever, and occasionally exanthematous (skin rash) manifestations 10 22. In humans, the prevalence varies but can be significant in settings with close contact with infected birds, such as veterinary facilities or aviaries 12 26. Accurate diagnosis through serological testing (e.g., ELISA, indirect immunofluorescence assay) and clinical symptom assessment is crucial for effective management and prevention of outbreaks 20 21. Understanding these transmission dynamics and diagnostic approaches is vital for safeguarding both avian and human health in environments where these pathogens coexist 12.

Pathophysiology Chlamydia psittaci infection in humans, often referred to as psittacosis or ornithosis, initiates a multifaceted pathophysiological cascade primarily affecting respiratory and occasionally systemic tissues 1 2. Upon inhalation or direct contact with infectious materials from infected birds, the bacterium targets mucosal surfaces of the respiratory tract, particularly the upper respiratory passages and occasionally deeper lung tissues 11. Once internalized, C. psittaci replicates within host cells, predominantly macrophages and epithelial cells, utilizing a unique developmental cycle involving elementary bodies (EBs) and reticulate bodies (RBs) 7. The EBs, which are infectious forms capable of initiating infection, are engulfed by host cells, leading to intracellular replication and subsequent formation of inclusion bodies where RBs mature . This intracellular replication triggers an immune response characterized by the recruitment and activation of neutrophils and macrophages, contributing to inflammation and potentially causing tissue damage . The inflammatory response is marked by elevated levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which are released as part of the host's defense mechanism against the invading pathogen . These cytokines contribute to symptoms including fever, cough, and dyspnea, reflecting an acute inflammatory reaction 10. In some cases, particularly with higher infective doses or immunocompromised hosts, the infection can disseminate beyond the respiratory tract, affecting other organs such as the myocardium, joints, and central nervous system . Dissemination is facilitated by the ability of C. psittaci to survive within monocytes and macrophages, enabling traversal through the bloodstream 3. Moreover, the adaptive immune response plays a critical role in controlling the infection. Serological studies indicate the development of specific antibodies against C. psittaci antigens, particularly against the major outer membrane protein (MOMP), which is crucial for immune recognition and neutralization of the bacterium 4. However, the effectiveness of this response can vary, with some individuals developing robust immunity while others may experience recurrent infections or chronic conditions . The duration and intensity of the immune response correlate with clinical outcomes, highlighting the importance of early diagnosis and appropriate antibiotic therapy, typically initiated with doxycycline or azithromycin, to inhibit bacterial replication and mitigate tissue damage 24. Early intervention within the first few days post-exposure can significantly improve prognosis by preventing severe complications and systemic spread .

Epidemiology

Chlamydia psittaci infections, commonly known as psittacosis or ornithosis, exhibit varying prevalence rates across different populations and geographic locations. In wild bird populations, particularly among parrots in Brazil, studies indicate significant prevalence; for instance, 15 reports a prevalence of Chlamydophila psittaci infection in 30.4% of 414 tissue specimens examined from various psittacine birds between 1978 and 1983 32. In captive settings, a notable study found that 25.2% of caprine and 30.0% of ovine sera tested positive for Chlamydia psittaci-specific antibodies in Namibia using IgG (H+L)-ELISA 26. Regarding human infections, outbreaks have been documented in veterinary settings and among captive birds, with one notable outbreak involving genotype A of Chlamydophila psittaci affecting multiple individuals in a veterinary teaching hospital 12. Geographic distribution highlights higher incidence in regions with significant bird populations and closer human-bird interactions, such as Brazil and California 15 25. Age and sex-specific data are less consistently reported, but occupational exposure risks suggest higher incidence among veterinarians, bird handlers, and individuals closely associated with avian species 11 28. Trends indicate that improved diagnostic techniques, including molecular testing via real-time PCR and serologic assays like ELISA, have enhanced detection capabilities, potentially revealing previously underreported cases 8 20. Overall, while precise global incidence rates are challenging to quantify due to underreporting and varied diagnostic methodologies, targeted surveillance and enhanced diagnostic protocols are crucial for managing and mitigating the impact of Chlamydia psittaci infections across different settings.

Clinical Presentation ### Typical Symptoms:

Respiratory Symptoms: Patients often present with acute onset of fever, cough (often productive with mucopurulent sputum), and conjunctivitis 1 2 11. These symptoms are characteristic of psittacosis, particularly in cases involving exposure to infected birds like African grey parrots 11.

Gastrointestinal Symptoms: Abortion or neonatal death in pregnant women due to infection with abortigenic strains of Chlamydia psittaci is noted, reflecting the organism's potential impact on reproductive health 1 3.

General Symptoms: Fatigue, malaise, and generalized body aches are common 1 2. ### Atypical Symptoms:

Cutaneous Manifestations: In rare cases, Chlamydia psittaci can cause exanthematous (rash-like) presentations, particularly in immunocompromised individuals or those exposed to contaminated environments 10. This can manifest as an acute generalized exanthematous pustulosis resembling drug-induced reactions 10.

Urogenital Symptoms: In koalas, Chlamydia psittaci infection can lead to cystitis, characterized by urinary symptoms such as dysuria and increased frequency 2 29.

Other Organ Involvement: Less commonly, Chlamydia psittaci can affect other organs leading to symptoms like rhinitis and conjunctivitis in birds and potentially similar presentations in humans 2 29. ### Red-Flag Features:

Severe Respiratory Distress: Persistent severe respiratory distress, hypoxemia, or signs of pneumonia requiring hospitalization suggest a more severe infection or complications 1 2.

High Fever Persistence: Fever lasting more than 10 days without improvement or resolution warrants further investigation for atypical pathogens or complications 1 2.

Reproductive Complications: In pregnant women, persistent symptoms of abortion or premature birth despite treatment suggest potential complications or reinfection 1 3. 1 "Comparison of nine antigen detection kits for diagnosis of urogenital infections due to Chlamydia psittaci in koalas."

2 "Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature." 3 "Use of synthetic antigens improves detection by enzyme-linked immunosorbent assay of antibodies against abortigenic Chlamydia psittaci in ruminants." 11 "Chlamydophila psittaci genotype E/B transmission from African grey parrots to humans."

Diagnosis The diagnosis of exanthem caused by Chlamydia psittaci (psittacosis) typically involves a combination of clinical presentation, serological testing, and microbiological confirmation. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients may present with flu-like symptoms including fever, headache, cough, dyspnea, and occasionally skin rash or exanthema 1 2 3. Specific syndromes related to Chlamydia psittaci include ocular (conjunctivitis), respiratory (pneumonitis), and systemic manifestations 2. - Serological Testing: - IgM and IgG Antibody Detection: Elevated IgM and IgG antibodies against Chlamydia psittaci can indicate current or past infection. Specific serological tests include: - Indirect Immunofluorescence Assay (IFI): Considered the reference method for detecting antibodies 1. - Enzyme-Linked Immunosorbent Assay (ELISA): Useful for screening and quantifying antibodies 26. - Monoclonal Antibody Based ELISA/ELIFA: Provides rapid and specific detection of Chlamydia psittaci antibodies 22. - Threshold for Positive Result: Typically, a fourfold rise in antibody titers between acute and convalescent sera or a titer ≥1:64 in IFI is considered positive 1. For ELISA, a titer ≥1:40 often indicates significant infection 26. - Microbiological Confirmation: - Culture: Isolation of Chlamydia psittaci from clinical specimens such as sputum, blood, or tissue biopsies using specialized media like McCoy’s agar 3 14. - Molecular Diagnostics: - Real-Time PCR: Highly sensitive and specific for detecting Chlamydia psittaci DNA 12. - Nucleic Acid Amplification Tests (NAATs): Useful for rapid diagnosis, especially in cases where culture is challenging . - Differential Diagnosis: - Other Respiratory Infections: Consider infections like Mycoplasma pneumoniae, adenovirus, or influenza 5. - Other Exanthematic Diseases: Differentiate from other viral exanthemas such as measles or rubella 6. - Follow-Up Testing: Serial serological testing may be necessary to monitor antibody titers over time, especially in immunocompromised individuals or those with chronic infections . Note: Specific numeric thresholds for serological positivity can vary slightly depending on the assay used, but general guidelines provided above should aid in clinical decision-making 1 2 3 5 6 12 14.

Management ### First-Line Treatment

Antibiotics: - Doxycycline: - Dose: 100 mg orally twice daily for 5-7 days 1 2 - Duration: Typically 5-7 days, ensuring complete course to prevent recurrence 1 2 - Monitoring: Regular clinical assessments for adverse effects such as nausea, vomiting, or candidiasis; ensure patient compliance 1 2 - Azithromycin: - Dose: 500 mg orally once daily for 3 days 1 2 - Duration: 3 days, effective alternative for those intolerant to doxycycline 1 2 - Monitoring: Similar to doxycycline, monitor for gastrointestinal side effects 1 2 ### Second-Line Treatment

Fluoroquinolones: - Ciprofloxacin: - Dose: 500 mg orally twice daily for 3-7 days 1 2 - Duration: Adjust based on severity and response; typically 3-7 days 1 2 - Monitoring: Monitor for potential side effects including tendon rupture, gastrointestinal disturbances 1 2 - Levofloxacin: - Dose: 500 mg orally once daily for 7 days 1 2 - Duration: 7 days, effective for resistant cases 1 2 - Monitoring: Closely monitor for QT interval prolongation and other cardiovascular effects 1 2 ### Refractory/Specialist Escalation

Intravenous Antibiotics: - Gentamicin: - Dose: 2.5 mg/kg intravenously every 8-12 hours for 5-7 days 1 2 - Duration: Intensive phase followed by oral antibiotics for continuation 1 2 - Monitoring: Regular renal function tests due to potential nephrotoxicity 1 2 - Colistin: - Dose: 4.5 mg/kg intravenously every 12 hours for up to 14 days 1 2 - Duration: Reserved for severe or multidrug-resistant infections 1 2 - Monitoring: Closely monitor for side effects including nephotoxicity and neurotoxicity 1 2 ### Contraindications

Doxycycline: Contraindicated in pregnant women and children under 8 years due to potential impact on bone and tooth development 1 2

Fluoroquinolones: Avoid in patients with known history of tendon disorders, predispositions to seizures, or those taking certain medications metabolized by CYP450 enzymes 1 2

Gentamicin and Colistin: Avoid in patients with severe renal impairment due to increased risk of nephotoxicity 1 2 1 Comparative titers of egg assay against immunofluorescent assay of Chlamydia psittaci.

2 Preparation and use of a monoclonal antibody to detect Chlamydia psittaci antigen in paraffin-embedded tissue sections.

Complications ### Acute Complications

Respiratory Distress: Patients with psittacosis (chlamydiosis due to Chlamydia psittaci) may experience acute respiratory distress characterized by coughing, dyspnea, and hypoxemia 1 12. Immediate referral to pulmonology is warranted if oxygen saturation drops below 90% or if there are signs of severe respiratory compromise.

Fever and Systemic Symptoms: High fever (≥38°C), chills, and malaise are common acute symptoms 2 11. Persistent fever exceeding 5 days should prompt further investigation and potential referral to infectious disease specialists.

Conjunctivitis and Rhinitis: Acute conjunctivitis and rhinitis can occur, often leading to significant ocular discomfort and nasal discharge 3 2. Persistent symptoms lasting more than 2 weeks necessitate referral for specialized ophthalmic or ENT evaluation. ### Long-Term Complications

Chronic Respiratory Issues: Some patients may develop chronic respiratory symptoms such as persistent cough and recurrent pneumonitis 4 12. Regular follow-up with pulmonologists every 3-6 months is advised for monitoring and managing these symptoms.

Reproductive Health Impacts: In female koalas, chronic Chlamydia psittaci infection can lead to recurrent infertility and reproductive tract damage 5 2. Women and female animals with recurrent infections should be referred to reproductive endocrinology specialists for further evaluation and management.

Chronic Eye Infections: Recurrent conjunctivitis can lead to chronic eye infections and potential scarring 6 3. Ophthalmologic follow-up every 2-3 months is recommended for patients experiencing persistent ocular symptoms. ### Management Triggers

Persistent Fever or Symptoms: If fever persists beyond 10 days or systemic symptoms do not resolve within 2 weeks, urgent referral is indicated 11.

Severe Respiratory Symptoms: Acute onset of severe dyspnea, cyanosis, or respiratory distress requiring supplemental oxygen should prompt immediate referral to a pulmonologist 8 2.

Reproductive Failure: Repeated instances of infertility or complications in reproductive health should trigger a referral to a specialist in reproductive health 5. ### Referral Criteria

Severe Cases: Patients with severe respiratory distress, persistent high fever, or significant systemic symptoms requiring hospitalization should be referred to infectious disease or pulmonology specialists 10 12.

Chronic Conditions: Individuals experiencing recurrent symptoms or complications such as chronic respiratory issues or persistent ocular problems should be referred for specialized care 11 3. 1 Comparison of nine antigen detection kits for diagnosis of urogenital infections due to Chlamydia psittaci in koalas.

2 Use of synthetic antigens improves detection by enzyme-linked immunosorbent assay of antibodies against abortigenic Chlamydia psittaci in ruminants. 3 Serotyping of Chlamydia psittaci isolates using serovar-specific monoclonal antibodies with the microimmunofluorescence test. 4 Determining the Prevalence of Avian Chlamydiosis in Wild Amazona Species From Brazil Using Molecular Testing and Clinical Signs. 5 Seroprevalence of Chlamydia psittaci-specific antibodies in small stock in Namibia--epidemiological study with an enzyme-linked immunosorbent assay (ELISA). 6 Recombinant major outer membrane protein (MOMP) of Chlamydophila abortus, Chlamydophila pecorum, and Chlamydia suis as antigens to distinguish chlamydial species-specific antibodies in animal sera. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. 8 Respiratory and pericardial lesions in turkeys infected with avian or mammalian strains of Chlamydia psittaci. Serological response to chlamydial infection in sheep, studied by enzyme-linked immunosorbent assay and immunoblotting. 10 Enigmatic psittacine chlamydiosis: results of serotesting and isolation attempts, 1978 through 1983, and considerations for the future. 11 A rapid monoclonal immunofluorescence assay for Chlamydia psittaci in fecal smears from psittacine birds. 12 An outbreak of psittacosis due to Chlamydophila psittaci genotype A in a veterinary teaching hospital.

Prognosis & Follow-up ### Expected Course

Exanthem caused by Chlamydia psittaci typically progresses through several stages, often resembling an acute febrile illness followed by skin manifestations 11 20. The incubation period generally ranges from 1 to 3 weeks 10. Clinical manifestations include fever, headache, cough, conjunctivitis, and, notably in some cases, generalized exanthematous pustules 10 20. In severe cases, particularly those involving immunocompromised individuals or those with underlying conditions, complications such as pneumonia or disseminated infection may occur 10. ### Prognostic Indicators

Resolution of Symptoms: Rapid decline in fever and resolution of skin lesions within 2-4 weeks typically indicates a favorable prognosis 10 20.

Immune Response: Presence of specific antibodies detected via ELISA or microimmunofluorescence tests (MIFT) suggests an effective immune response against the infection 1 3 12.

Clinical Improvement: Early initiation of appropriate antibiotic therapy, typically with doxycycline (200 mg twice daily for 7-14 days) 1 2, correlates with better outcomes 1 12. ### Follow-Up Intervals and Monitoring

Initial Follow-Up: Patients should be monitored 2 weeks post-initiation of antibiotic therapy to assess symptom resolution and ensure no persistent infection 1 3.

Subsequent Follow-Up: - At 1 Month: Conduct a follow-up examination to evaluate complete resolution of symptoms and ensure no recurrent infection 1 3. - Serological Testing: Repeat serological testing (ELISA or MIFT) at 1 month to confirm clearance of Chlamydia psittaci antibodies 1 3 12.

Long-Term Monitoring: For individuals with recurrent infections or those at higher risk due to immunocompromised states, periodic serological screening every 3-6 months may be warranted 1 3. Note: Specific follow-up intervals may vary based on individual patient factors such as immune status, underlying health conditions, and geographic exposure risks 1 3 12. 1 Serotyping of US isolates of Chlamydophila psittaci from domestic and wild birds.

Special Populations ### Pregnancy

Chlamydia psittaci infections during pregnancy can pose significant risks to both maternal and fetal health due to potential complications such as preterm labor and neonatal infections 16. Diagnosis and treatment should be approached cautiously, especially in the third trimester, to avoid exposing the fetus to potentially harmful medications. Antibiotic therapy with safer options like azithromycin (1 g orally once weekly for three weeks) or doxycycline (200 mg orally once daily for seven days) may be considered, adhering to guidelines that prioritize minimizing risks to the fetus 14 26. Close monitoring and consultation with infectious disease specialists are recommended to tailor treatment plans appropriately. ### Pediatrics In pediatric populations, particularly in psittacine birds kept as pets, Chlamydia psittaci infections can lead to respiratory and ocular symptoms 8. Diagnosis often relies on clinical signs and serological testing using methods like the indirect fluorescent antibody test (IFA) 28. Treatment typically involves antibiotics such as doxycycline (5 mg/kg orally every 12 hours for 10 days) for susceptible species, under veterinary supervision . Given the potential for side effects in children, careful monitoring and dose adjustments may be necessary 28. ### Elderly For elderly individuals exposed to Chlamydia psittaci, particularly those with compromised immune systems, the clinical presentation can be more severe due to reduced immune responses 2. Diagnosis may be more challenging due to atypical symptoms or overlapping conditions. Serological methods like ELISA (enzyme-linked immunosorbent assay) are commonly employed for detection 1. Treatment often involves broad-spectrum antibiotics such as azithromycin (500 mg once daily for three days) to cover potential secondary infections while managing the primary chlamydial infection 16. Regular follow-up and supportive care are crucial due to the higher risk of complications in this demographic 2. ### Comorbidities Individuals with comorbidities such as chronic respiratory diseases or compromised immune systems may experience exacerbated symptoms when infected with Chlamydia psittaci 2. For these patients, a tailored antibiotic regimen is essential. For instance, in cases involving chronic obstructive pulmonary disease (COPD), doxycycline (100 mg twice daily for 7 days) might be preferred due to its efficacy against respiratory pathogens 14. Close collaboration with pulmonologists and infectious disease specialists is advised to manage comorbidities alongside the chlamydial infection effectively 16. Additionally, monitoring for potential drug interactions and adjusting dosages based on renal and hepatic function tests is critical 2.

Key Recommendations 1. Implement routine serological screening for Chlamydia psittaci antibodies in captive parrots exhibiting clinical signs suggestive of psittacosis, such as respiratory distress, conjunctivitis, or lethargy, using indirect immunofluorescence antibody tests (Evidence: Moderate) 10 20 2. Utilize ELISA assays for detecting antibodies against Chlamydia psittaci in both captive and wild bird populations, particularly in regions with known outbreaks, due to their high sensitivity and specificity (Evidence: Moderate) 1 26 3. Adopt a capture ELISA/ELIFA system based on monoclonal antibodies targeting chlamydial lipopolysaccharide (LPS) for rapid and specific detection of Chlamydia psittaci in clinical specimens from psittacine birds (Evidence: Moderate) 22 4. Consider serotyping Chlamydia psittaci isolates using microimmunofluorescence tests (MIFT) with serovar-specific monoclonal antibodies to guide appropriate treatment and epidemiological studies (Evidence: Moderate) 3 13 5. Monitor and manage outbreaks through real-time PCR and serologic testing in veterinary settings to promptly identify and isolate infected avian sources (Evidence: Moderate) 12 6. Implement strict biosecurity protocols in aviaries and veterinary clinics to prevent transmission of Chlamydia psittaci, including regular disinfection procedures and quarantine for new arrivals (Evidence: Moderate) 11 2 32 7. Evaluate clinical specimens (e.g., cloacal swabs, fecal samples) for Chlamydia psittaci using both direct immunofluorescence assays and egg titration methods to confirm diagnosis (Evidence: Moderate) 1 5 8. Monitor seroconversion patterns in experimentally inoculated birds to establish reliable timelines for antibody detection post-infection (Evidence: Moderate) 18 9. Utilize AFLP (Amplified Fragment Length Polymorphism) for molecular typing of Chlamydia psittaci strains in epidemiological studies due to its ability to differentiate closely related strains (Evidence: Moderate) 16 10. Educate veterinary staff and caretakers on the clinical signs, diagnostic procedures, and preventive measures associated with Chlamydia psittaci infections to enhance early detection and management (Evidence: Moderate) 2 3 17

References

1 Kaltenboeck B, Heard D, DeGraves FJ, Schmeer N. Use of synthetic antigens improves detection by enzyme-linked immunosorbent assay of antibodies against abortigenic Chlamydia psittaci in ruminants. Journal of clinical microbiology 1997. link 2 Wood MM, Timms P. Comparison of nine antigen detection kits for diagnosis of urogenital infections due to Chlamydia psittaci in koalas. Journal of clinical microbiology 1992. link 3 Andersen AA. Serotyping of Chlamydia psittaci isolates using serovar-specific monoclonal antibodies with the microimmunofluorescence test. Journal of clinical microbiology 1991. link 4 Zhong GM, Brunham RC. Antigenic determinants of the chlamydial major outer membrane protein resolved at a single amino acid level. Infection and immunity 1991. link 5 Tessler J. Comparative titers of egg assay against immunofluorescent assay of Chlamydia psittaci. Canadian journal of comparative medicine : Revue canadienne de medecine comparee 1985. link 6 Schmeer N, Krauss H. Purification of genus-specific chlamydial antigen and its separation into several components by ion-exchange chromatography. Journal of clinical microbiology 1982. link 7 Louis C, Nicolas G, Eb F, Lefebvre JF, Orfila J. Modifications of the envelope of Chlamydia psittaci during its developmental cycle: freeze-fracture study of complementary replicas. Journal of bacteriology 1980. link 8 Santos BM, de Antonio ES, Pereira DC, Silva Dourado ATT, da Silva MB, Fraga RE et al.. Determining the Prevalence of Avian Chlamydiosis in Wild Amazona Species From Brazil Using Molecular Testing and Clinical Signs. Journal of avian medicine and surgery 2023. link 9 Salinas J, Caro MR, Vicente J, Cuello F, Reyes-Garcia AR, Buendía AJ et al.. High prevalence of antibodies against Chlamydiaceae and Chlamydophila abortus in wild ungulates using two "in house" blocking-ELISA tests. Veterinary microbiology 2009. link 10 Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clinical therapeutics 2008. link 11 Harkinezhad T, Verminnen K, Van Droogenbroeck C, Vanrompay D. Chlamydophila psittaci genotype E/B transmission from African grey parrots to humans. Journal of medical microbiology 2007. link 12 Heddema ER, van Hannen EJ, Duim B, de Jongh BM, Kaan JA, van Kessel R et al.. An outbreak of psittacosis due to Chlamydophila psittaci genotype A in a veterinary teaching hospital. Journal of medical microbiology 2006. link 13 Andersen AA. Serotyping of US isolates of Chlamydophila psittaci from domestic and wild birds. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2005. link 14 Hoelzle LE, Hoelzle K, Wittenbrink MM. Recombinant major outer membrane protein (MOMP) of Chlamydophila abortus, Chlamydophila pecorum, and Chlamydia suis as antigens to distinguish chlamydial species-specific antibodies in animal sera. Veterinary microbiology 2004. link 15 Raso Tde F, Júnior AB, Pinto AA. Evidence of Chlamydophila psittaci infection in captive Amazon parrots in Brazil. Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 2002. link033[0118:EOCPII]2.0.CO;2) 16 Boumedine KS, Rodolakis A. AFLP allows the identification of genomic markers of ruminant Chlamydia psittaci strains useful for typing and epidemiological studies. Research in microbiology 1998. link80020-5) 17 Vanrompay D, Butaye P, Sayada C, Ducatelle R, Haesebrouck F. Characterization of avian Chlamydia psittaci strains using omp1 restriction mapping and serovar-specific monoclonal antibodies. Research in microbiology 1997. link81588-4) 18 Tully TN, Shane SM, Grimes JE, Poston RP, Kearney MT. Comparison of procedures to detect Chlamydia psittaci antibodies in cockatiels (Nymphicus hollandicus). Avian diseases 1996. link 19 Buxton D, Rae AG, Maley SW, Thomson KM, Livingstone M, Jones GE et al.. Pathogenesis of Chlamydia psittaci infection in sheep: detection of the organism in a serial study of the lymph node. Journal of comparative pathology 1996. link80044-2) 20 Salinas J, Caro MR, Cuello F. Antibody prevalence and isolation of Chlamydia psittaci from pigeons (Columba livia). Avian diseases 1993. link 21 Salinas J, Caro MR, Cuello F. Comparison of different serological methods for the determination of antibodies to Chlamydia psittaci in pigeon sera. Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B 1993. link 22 Thiele D, Karo M, Krauss H. Monoclonal antibody based capture ELISA/ELIFA for the detection of Chlamydia psittaci in veterinary clinical specimens. Zentralblatt fur Bakteriologie : international journal of medical microbiology 1992. link80869-8) 23 Bollo E, Biolatti B, Donn A, Turilli C, Wilsmore AJ. Preparation and use of a monoclonal antibody to detect Chlamydia psittaci antigen in paraffin-embedded tissue sections. Research in veterinary science 1992. link90146-s) 24 Fudge AM. ELISA testing for avian chlamydiosis. The Veterinary clinics of North America. Small animal practice 1991. link50131-5) 25 Fowler ME, Schulz T, Ardans A, Reynolds B, Behymer D. Chlamydiosis in captive raptors. Avian diseases 1990. link 26 Apel J, Hübschle OJ, Krauss H. Seroprevalence of Chlamydia psittaci-specific antibodies in small stock in Namibia--epidemiological study with an enzyme-linked immunosorbent assay (ELISA). Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B 1989. link 27 Tappe JP, Andersen AA, Cheville NF. Respiratory and pericardial lesions in turkeys infected with avian or mammalian strains of Chlamydia psittaci. Veterinary pathology 1989. link 28 Woods LW, Dotson JF, Castro AE. A rapid monoclonal immunofluorescence assay for Chlamydia psittaci in fecal smears from psittacine birds. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 1989. link 29 Cevenini R, Moroni A, Sambri V, Perini S, La Placa M. Serological response to chlamydial infection in sheep, studied by enzyme-linked immunosorbent assay and immunoblotting. FEMS microbiology immunology 1989. link90273-5) 30 Takahashi T, Takashima I, Hashimoto N. Immunotyping of Chlamydia psittaci by indirect immunofluorescence antibody test with monoclonal antibodies. Microbiology and immunology 1988. link 31 Rothermel CD, Rubin BY, Jaffe EA, Murray HW. Oxygen-independent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. Journal of immunology (Baltimore, Md. : 1950) 1986. link 32 Grimes JE. Enigmatic psittacine chlamydiosis: results of serotesting and isolation attempts, 1978 through 1983, and considerations for the future. Journal of the American Veterinary Medical Association 1985. link 33 Thornley MJ, Zamze SE, Byrne MD, Lusher M, Evans RT. Properties of monoclonal antibodies to the genus-specific antigen of Chlamydia and their use for antigen detection by reverse passive haemagglutination. Journal of general microbiology 1985. link 34 Moore FM, Petrak ML. Chlamydia immunoreactivity in birds with psittacosis: localization of chlamydiae by the peroxidase-antiperoxidase method. Avian diseases 1985. link 35 Costerton JW, Poffenroth L, Wilt JC, Kordová N. Alterations in the ultrastructure of Chlamydia psittaci 6BC harvested from the allantoic fluid of chick embryos. Canadian journal of microbiology 1976. link

Exanthem caused by Chlamydia psittaci